---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-124047"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T17:03:58.340299+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# AbbVie to acquire Cerevel Therapeutics for $45/share (~$8.7B equity value)

## Summary
- Transaction valued at $45.00 per Cerevel share, total equity ~$8.7B; approved by both boards.
- Cerevel's late-stage asset emraclidine is a potential best-in-class antipsychotic for schizophrenia.
- Deal expected to close mid-2024, subject to Cerevel shareholder vote, regulatory approvals, and customary conditions.
- Acquisition adds multiple clinical assets: tavapadon (Parkinson's), CVL-354 (MDD), darigabat (epilepsy/panic).
- AbbVie expects transaction to be accretive to adjusted diluted EPS beginning in 2030.

## SEC filing metadata
- accession: 0001104659-23-124047
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465923124047/0001104659-23-124047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465923124047/tm2332303d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-124047
- JSON: https://secwatch.observer/filing/0001104659-23-124047.json
- Plain text: https://secwatch.observer/filing/0001104659-23-124047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.